MedPath

Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis

Conditions
Decompensated Cirrhosis
Hepatitis B
Interventions
Other: no intervention
Registration Number
NCT05086536
Lead Sponsor
Beijing Friendship Hospital
Brief Summary

In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage). Patients were followed up every 6 months until death /liver transplantation or for 5 years. Clinical data from medical records about past history, first decompensated events, second /further decompensated events, HCC, and death/ liver transplantation were retrospectively collected. In this retrospective study, the incidence of re-compensation and its clinical characteristics were mainly explored.

Detailed Description

In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage). Patients were followed up every 6 months until death /liver transplantation or for 5 years. WBC, RBC, HGB, PLT, CRP, PT, PTA, INR, ALT, AST, TB, DB, ALB, GLO, ALP, GGT, CHE, BUN, Cr, Na, GLU, CHOL, TG, HDL-C, LDL-C, AFP, HBsAg, HBV-DNA, LSM, BUS, MRI/CT and gastroscope from medical records about past history, first decompensated events, second /further decompensated events, HCC, and death/ liver transplantation were retrospectively collected. This retrospective study aimed to explore the incidence of re-compensation and its clinical characteristics.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
600
Inclusion Criteria
  1. Ascites and/or variceal hemorrhage (VH) as the first decompensated events;

  2. Initiating antiviral therapy within 3 months of the first decompensated events;

  3. Clinical parameters were available at the first decompensated events, including PLT, ALT, ALB, TB, PT/INR, Cr, HBV DNA, BUS,

  4. Clinical outcomes were classified:

    1. Without further decompensation: medical records at year-1, year 2 to 4, and year-5 were available.
    2. With ≥ 2 episodes of decompensation: medical records for decompensation were available.
Exclusion Criteria
  1. Hepatocellular carcinoma prior to /within 6 months of first decompensated events;
  2. Liver transplantation /death within 6 months of first decompensated events;
  3. complicated with other chronic liver diseases, including HCV, DILI, AIH, NAFLD, ALD.
  4. Any complication of severe heart, lung, kidney, brain, blood diseases or other severe systematic diseases;
  5. Pregnant women.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
early stage decompensation cohortno interventionPatients occurred first decompensated events and initiating nucleoside analogs (NUCs) based treatment within 3 months were retrospectively included.
Primary Outcome Measures
NameTimeMethod
Cumulative incidence of re-compensationYear 5

Patients who did not occur further decompensation

Secondary Outcome Measures
NameTimeMethod
Cumulative incidence of re-compensationYear 1, 2, 3, and 4

Patients who did not occur further decompensation

Annual incidence of second decompensationYear 1, 2, 3, 4, and 5

Patients who occurred second decompensation

Cumulative incidence of liver-related death / liver transplantationYear 1, 2, 3, 4, and 5

Patients who died of decompensation

Dynamic changes of Child-Pugh score in re-compensated and not re-compensated groupYear 1, 2, 3, 4, and 5

Child-Pugh

Dynamic changes of APRI score in re-compensated and not re-compensated groupYear 1, 2, 3, 4, and 5

APRI

Dynamic changes of FIB-4 score in re-compensated and not re-compensated groupYear 1, 2, 3, 4, and 5

FIB-4

Dynamic changes of liver stiffness values measured by Transient Elastography in re-compensated and not re-compensated groupYear 1, 2, 3, 4, and 5

Liver stiffness

Cumulative incidence of HCCYear 1, 2, 3, 4, and 5

Patients who occurred HCC

Dynamic changes of MELD score in re-compensated and not re-compensated groupYear 1, 2, 3, 4, and 5

MELD

Trial Locations

Locations (7)

The Second Affiliated Hospital of Baotou Medical Coll

🇨🇳

Baotou, Inner Mongolia, China

Shandong Provincial Hospital

🇨🇳

Jinan, Shandong, China

Beijing Friendship Hospital, Capital Medical University

🇨🇳

Beijing, Beijing, China

The Affiliated Hospital of Qingdao University

🇨🇳

Qingdao, Shandong, China

XiangYa Hospital Central South University

🇨🇳

Changsha, Hunan, China

Beijing YouAn Hospital, Capital Medical University

🇨🇳

Beijing, Beijing, China

First Hospital of Shanxi Medical University

🇨🇳

Taiyuan, Shanxi, China

© Copyright 2025. All Rights Reserved by MedPath